Sunesis Pharmaceuticals - A new BTK for a new day
Sunesis remains on track to complete the dose-escalation portion of its Phase Ib/II clinical trial for lead compound SNS-062, an oral Bruton’s...
64 Views
SNS-062 trial up and running
Sunesis announced on 18 July 2017 that the first patient had been dosed in its Phase Ib/II study of SNS-062 for the treatment of chronic...
77 Views
Redirection after EMA application pulled
Sunesis reported in May 2017 that it has pulled its application to the EMA for the approval of vosaroxin for the treatment of acute myeloid...
144 Views
Getting closer to EU approval
The company’s application for EU approval for vosaroxin approval in AML continues to progress. The company will go before the Oncology Division of...
34 Views